Maze Therapeutics, Inc. (MAZE) Stock Price & Analysis
Maze Therapeutics, Inc. (MAZE) closed at USD 31.93 on Thursday, October 29, 2026, up 0.63% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 31.73; the Oct 29, 2026 session ranged USD 31.56–32.63 on volume of 417,914 shares. Market capitalization is $1.77B, with a 52-week range of USD 21.95–53.65 (NGM). Source: Nexqual, retrieved October 29, 2026 at 23:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MAZE.md
Key facts (MAZE)
- Analysts: Buy (mean 1.93 on a 1–5 scale) (14 analysts), mean target USD 62.54 (range 46–110).
- Total return with dividends: 1Y -3.9% vs S&P 500 +14.4%; 5Y +100.2% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05 (date not yet confirmed by the company), EPS estimate USD -0.75, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: MAZE paid no cash dividend in the last five years.
- Short interest: 15.26% of float (as of 2026-10-15), 8.3 days to cover.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MAZE)
P/B 3.9x · FCF yield -6.11% · Earnings yield -7.64% · Net cash $372M · EV $1.38B
Analysts (MAZE)
Consensus Buy (mean 1.93 on a 1–5 scale), 14 analysts; mean target USD 62.54 (low 46, high 110).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Initiated | Buy | $75 |
| 2026-09-24 | HC Wainwright & Co. | Reiterated | Buy | $110 |
| 2026-09-23 | Citigroup | Initiated | Buy | $50 |
| 2026-09-23 | Wedbush | Reiterated | Outperform | $48 |
| 2026-09-22 | BTIG | Reiterated | Buy | $46 |
| 2026-08-12 | BTIG | Reiterated | Buy | $46 |
Total return (dividends reinvested) (MAZE)
| 1Y (from 2025-10-30) | 5Y (from 2025-01-27) | |
|---|---|---|
| Total return | -3.9% | +100.2% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -3.9% | +48.5% |
| Volatility (annualized) | 70.7% | 80.0% |
| Max drawdown | -56.8% (Mar 2026→Sep 2026) | -55.1% (Mar 2026→Sep 2026) |
Dividends (MAZE)
MAZE paid no cash dividend in the last five years.
Short interest (MAZE)
7,527,939 shares sold short, 15.26% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 5,678,289 shares (+32.6%). Days to cover: 8.3 (short shares ÷ average daily volume).
MAZE earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.76 | −$0.70 | Miss −8.6% | — |
| — | Quarter ended Dec 31, 2025 | −$0.65 | −$0.69 | Beat +5.8% | — |
| — | Quarter ended Sep 30, 2025 | −$0.66 | −$0.69 | Beat +4.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
MAZE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.75 | $-0.75 | $0.00 | $0 | 10 |
| Next quarter (ends Dec 2026) | $-0.79 | $-0.78 | −$0.01 | $0 | 10 |
| Current fiscal year (ends Dec 2026) | $-2.73 | $-2.67 | −$0.05 | $20.0M | 10 |
| Next fiscal year (ends Dec 2027) | $-3.19 | $-3.19 | $0.00 | $7.5M | 10 |
Key Statistics (as of October 29, 2026 at 23:43 UTC)
| Price | USD 31.93 |
|---|---|
| Change | ▲ 0.63% (up) |
| Previous Close | USD 31.73 |
| Open | USD 32.17 |
| Day Range | USD 31.56 – 32.63 |
| 52-Week Range | USD 21.95 – 53.65 |
| Volume | 417,914 shares |
| Market Cap | $1.77B |
| Exchange | NGM |
Technical Analysis (MAZE)
Nexqual's technical model rates MAZE "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 23:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.62 (neutral) |
| vs SMA50 | Above (USD 27.44) |
| MACD | 1.46 (positive) |
Analyst Ratings (MAZE)
Wall Street analysts rate MAZE "Buy" based on 14 analysts, with a mean price target of USD 62.54 (range USD 46–110), per Nexqual as of October 29, 2026 at 23:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 62.54 |
| High Target | USD 110 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 14 / 0 / 0 |
Earnings (MAZE)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.75 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.76 vs est -0.7 ▼ miss |
| 2025-12-31 | USD -0.65 vs est -0.69 ▲ beat |
| 2025-09-30 | USD -0.66 vs est -0.69 ▲ beat |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Financials & Fundamentals (MAZE)
| Total Revenue | $20.00M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -728.06% |
| Profit Margin | +0.00% |
| ROE | -37.35% |
| Debt / Equity | 0.13 |
| Current Ratio | 18.31 |
| Total Cash | $411.09M |
| Total Debt | $60.42M |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Financial Health Score (MAZE)
Nexqual rates Maze Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 23:43 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $411M cash vs $60M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$112M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -37%, ROA -21.8% |
Ownership (MAZE)
| Insider Ownership | +1.58% |
|---|---|
| Institutional Ownership | +110.17% |
| Shares Outstanding | 55.55M |
| Float | 36.80M |
| Short % of Float | +15.26% |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Leadership (MAZE)
Maze Therapeutics, Inc. is led by Jason V. Coloma M.B.A., M.P.H., CEO & Director, per Nexqual as of October 29, 2026 at 23:43 UTC.
| CEO & Director | Jason V. Coloma M.B.A., M.P.H. |
|---|---|
| CFO & Principal Accounting Officer | Misbah Tahir |
| President of Research & Development and Chief Medical Officer | Harold S. Bernstein |
| Senior Vice President of Technology and Business Operations | Vipin Vijayakumar |
| Chief Scientific Officer | Maarten Hoek |
Major Backers & Investors (MAZE)
Notable institutional backers of Maze Therapeutics, Inc. include Frazier Life Sciences Management, L.P. , TRV GP IV, LLC, Arch Venture Management, Llc, according to Nexqual as of October 29, 2026 at 23:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 9.06% |
| TRV GP IV, LLC | 8.05% |
| Arch Venture Management, Llc | 7.42% |
| Deep Track Capital, Lp | 6.72% |
| Jupiter Topco LLC | 6.14% |
| T. Rowe Price | 4.69% |
| Logos Global Management LP | 3.48% |
| a16z Capital Management, L.L.C. | 3.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.31% |
| Vanguard Group | 3.2% |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
From Maze Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Compass Platform: We intend to leverage our proprietary Compass platform to expand our precision medicine pipeline by identifying and prioritizing novel drug targets in subsets of kidney and metabolic diseases with significant unmet need.
- Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug discovery and development.
- Consequently, we may not obtain or maintain adequate patent protection for any of our proprietary technologies or current or future therapeutic candidates.
- We also seek to protect our proprietary information and trade secrets by entering into confidentiality and invention assignment agreements with our employees, consultants and other parties who have access to such information.
Legal & Regulatory Risks (Item 1A, quoted)
- Our current and future relationships with customers and third-party payors may be subject to applicable anti-kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, which could expose us to significant penalties, including criminal, civil, and administrative penalties, contractual damages, reputational harm and diminished profits and future earnings.
- We expect that additional state and federal healthcare reform measures may be adopted in the future.
- Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.
- Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain therapeutic candidates outside of the United States and require us to develop and implement costly compliance programs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt